Analysis

Immutep Ltd (IMM) Stock Analysis

Immutep Ltd investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to IMM.

websiteIMM/analysis/IMM

Immutep Ltd

Immutep Ltd investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to IMM.

Stock profile

Ticker

IMM

Asset type

Stock

Market cap

$50.6M

Sector

Health Technology

Industry

Biotechnology

Currency

AUD

Ticker listings

Immutep Ltd may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • IMM primary listing
  • IMMP
  • YP1B
  • A2H81H
  • A2H8YL
  • PRRUF
  • YP1A

Latest Immutep Ltd news

Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cance...

SYDNEY, AUSTRALIA, May 28, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company targeting cance...

Immutep : Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-s...

Immutep : Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer

Immutep Receives Nasdaq Notice of Bid Price Deficiency

SYDNEY, AUSTRALIA, April 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), advises that it has received a written notification ...

Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

SYDNEY, AUSTRALIA, April 22, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage immunotherapy company targeting can...

Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma

SYDNEY, AUSTRALIA, April 15, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company targeting can...

Research sections

Valuation

Review valuation context for Immutep Ltd.

Future growth

Review future growth context for Immutep Ltd.

Past performance

Review past performance context for Immutep Ltd.

Financial health

Review financial health context for Immutep Ltd.

Dividend

Review dividend context for Immutep Ltd.

Management

Review management context for Immutep Ltd.

Ownership

Review ownership context for Immutep Ltd.

Other information

Review other information context for Immutep Ltd.

Community

Review community context for Immutep Ltd.